Notice of Expiration of PAR-15-289 "The Pancreatic Cancer Detection Consortium (U01)"

Notice Number: NOT-CA-18-029

Key Dates
Release Date: December 8, 2017

Related Announcements
PAR-15-289

Issued by
National Cancer Institute (NCI)

Purpose

This Notice announces the expiration of PAR-15-289 "The Pancreatic Cancer Detection Consortium (U01)" effective immediately.

The following sections of Part 1. Overview Information, Key Dates are being modified:

Part 1. Overview Information

Key Dates

Currently reads
Application Due Date(s): November 25, 2015; May 26, 2016; September 21, 2016; May 26, 2017; September 21, 2017, April 6, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Modified to read
Application Due Date(s): November 25, 2015; May 26, 2016; September 21, 2016; May 26, 2017; September 21, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Currently reads
Scientific Merit Review: March/April 2016; September/October 2016; January/February 2017; September/October 2017; January/February 2018; June/July 2018

Modified to read
Scientific Merit Review: March/April 2016; September/October 2016; January/February 2017; September/October 2017; January/February 2018;

Currently reads
Advisory Council Review: May 2016; January 2017; May 2017; January 2018; May 2018; January 2019 per issuance of NOT-CA-16-024.

Modified to read
Advisory Council Review: May 2016; January 2017; May 2017; January 2018; May 2018; per issuance of NOT-CA-16-024

Currently reads
Earliest Start Date: July 2016; April 2017; July 2017; April 2018; July 2018; December 2018

Modified to read
Earliest Start Date: July 2016; April 2017; July 2017; April 2018; July 2018

Currently reads:
Expiration Date: April 7, 2018

Modified to read
Expiration Date: December 15, 2017

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Sudhir Srivastava, PhD, MPH
National Cancer Institute (NCI)
Telephone: 240-276-7028
Email: [email protected]